This is a ready-to-use APR/PQR report template, the document the governing SOP produces each cycle. It is written to the fuller EU GMP Chapter 1 line-item list, which is a superset of the US 21 CFR 211.180(e) minimum, so one completed report satisfies both regimes. Replace every <<FILL: ...>> placeholder with your own specifics. A worked filled specimen follows the template. This document is educational reference, not legal or regulatory advice; confirm every cited regulation against the current published source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Report title | Annual Product Review / Product Quality Review |
| Report number | <<FILL: REP-ID, e.g. REP-QA-APR-2026-014>> |
| Linked SOP | <<FILL: SOP-ID for APR/PQR>> |
| Product(s) covered, strengths/presentations | <<FILL>> |
| Product grouping basis | <<FILL: one review across strengths/presentations, or separate reviews cross-referenced, with the reason>> |
| Marketing authorization / application number(s) | <<FILL: NDA/ANDA/BLA/MA number(s)>> |
| Manufacturing site(s) | <<FILL>> |
| Review period | <<FILL: from date>> to <<FILL: to date>> |
| Data cutoff date | <<FILL>> |
| Prepared by | <<FILL: role, e.g. APR/PQR coordinator>> |
1. Purpose and scope
This report reviews the manufacturing, testing, and quality event history of <<FILL: product name(s)>> for the review period stated above, to determine whether the specifications, the manufacturing process, or the controls need to change, per 21 CFR 211.180(e) and EU GMP Part I, Chapter 1, section 1.10. It covers all commercial batches manufactured in the period at the site(s) named above, including any contract manufacturing organization contribution.
2. Data set and completeness
State exactly what was analyzed so the report is re-derivable and reconciliation is demonstrated, not asserted.
| Field | Entry |
|---|---|
| Batches manufactured in period | <<FILL: count>> |
| Batches released / rejected / reworked / on hold at cutoff | <<FILL: counts, sum must equal batches manufactured>> |
| OOS count in period, per lab log | <<FILL>> |
| OOS count reflected in this review | <<FILL: must match>> |
| Deviation count in period, per deviation log | <<FILL>> |
| Deviation count reflected in this review | <<FILL: must match>> |
| Complaint count in period, per complaint system | <<FILL>> |
| Complaint count reflected in this review | <<FILL: must match>> |
| Records excluded from quantitative trending, with reason | <<FILL: none, or list>> |
| Data extract date(s) and source system(s)/query reference | <<FILL>> |
| Data pull reconciliation checklist reference | <<FILL: checklist ID, see the data pull reconciliation checklist>> |
3. Batch disposition summary
| Metric | This period | Prior period | Two periods ago |
|---|---|---|---|
| Batches manufactured | <<FILL>> | <<FILL>> | <<FILL>> |
| Batches released | <<FILL>> | <<FILL>> | <<FILL>> |
| Batches rejected (with reasons) | <<FILL>> | <<FILL>> | <<FILL>> |
| Batches reworked | <<FILL>> | <<FILL>> | <<FILL>> |
| Rejection rate | <<FILL>> | <<FILL>> | <<FILL>> |
| Any cluster by line, shift, or material lot | <<FILL>> |
4. Critical quality attribute and in-process control trending
One row per CQA/critical IPC. Attach or reference the control chart for each.
| Attribute | Specification | n (batches) | Mean | Cpk | Ppk | Run-rule violations | OOT determinations | Trend read |
|---|---|---|---|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: none / list>> | <<FILL: none / list>> | <<FILL: stable / drifting / OOT confirmed>> |
5. Categorical trending: deviations, OOS, complaints, returns, recalls
| Category | This period | Prior period | Two periods ago | Denominator | Rate this period | Trend read |
|---|---|---|---|---|---|---|---|
| Deviations, by top category | <<FILL>> | <<FILL>> | <<FILL>> | Per batch | <<FILL>> | <<FILL>> |
| OOS | <<FILL>> | <<FILL>> | <<FILL>> | Per batch | <<FILL>> | <<FILL>> |
| Complaints, by top defect type | <<FILL>> | <<FILL>> | <<FILL>> | Per million units distributed | <<FILL>> | <<FILL>> |
| Returns / salvage | <<FILL>> | <<FILL>> | <<FILL>> | Per batch | <<FILL>> | <<FILL>> |
| Recalls / field alerts | <<FILL: none, or reference>> | | | | | <<FILL>> |
6. Signal register
One row per signal surfaced by sections 4 or 5, evidence, and disposition. This section is the heart of the report; a maintained standalone version lives in the signal register / trend disposition log.
| Signal | Evidence | Disposition (justified acceptable / escalated) | Basis / CAPA reference |
|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
7. Stability
| Field | Entry |
|---|---|
| Annual commitment batches placed in period | <<FILL: count, batch numbers>> |
| Active stability studies covering this product | <<FILL>> |
| Adverse trends identified, any station | <<FILL: none, or describe with reference>> |
| OOS or confirmed OOT on stability in period | <<FILL: none, or reference and Field Alert Report status>> |
| Shelf life still supported by current data | Yes / No, basis <<FILL>> |
8. Change control review (“change creep” check)
| Field | Entry |
|---|---|
| Change controls approved in period, count | <<FILL>> |
| Reviewed as a set against period batch data for cumulative drift | Yes / No |
| Cumulative drift identified | <<FILL: none, or describe>> |
| Revalidation triggered where required | Yes / No / N/A, reference <<FILL>> |
| Variation/supplement filing required by any change | Yes / No, reference <<FILL>> |
9. Materials and suppliers
| Field | Entry |
|---|---|
| New material sources introduced in period | <<FILL: none, or list with qualification status>> |
| Incoming material rejections | <<FILL: count, reasons>> |
| Traceability gaps identified | <<FILL: none, or describe>> |
10. Equipment and utility qualification status
| Field | Entry |
|---|---|
| Equipment requalification due in period, completed on time | <<FILL>> |
| Overdue requalification | <<FILL: none, or list>> |
| Utility (water, HVAC, compressed gas) excursions affecting the product | <<FILL: none, or reference>> |
11. Marketing authorization / variation status
| Field | Entry |
|---|---|
| Variations / supplements filed in period | <<FILL>> |
| Variations granted | <<FILL>> |
| Variations refused or withdrawn | <<FILL>> |
| Post-marketing commitments due in period | <<FILL>> |
| Registered process vs. as-run process confirmed consistent | Yes / No, basis <<FILL>> |
12. Technical and quality agreement currency (contract sites)
| Contract site | Activity performed | Quality agreement reference | Currency confirmed | Data contribution received on time, at required level of detail |
|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | Yes / No | Yes / No |
13. Prior period action review
| Prior signal / CAPA reference | Original disposition | Closed? | Effectiveness verified? | Notes |
|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
14. Conclusion
| Question | Answer | Basis |
|---|---|---|
| Do the specifications need to change? | <<FILL: Yes / No>> | <<FILL>> |
| Does the manufacturing process need to change? | <<FILL: Yes / No>> | <<FILL>> |
| Do the in-process controls need to change? | <<FILL: Yes / No>> | <<FILL>> |
| Overall product state | <<FILL: in control / drifting, monitored / out of control, action required>> | |
| CAPAs opened from this review | <<FILL: numbers, or "none">> | |
| Variations/supplements triggered | <<FILL: numbers, or "none">> |
State the conclusion in plain terms, tied directly to the trending and the signal register above. A conclusion that does not match the data visible in sections 4 through 6 is the single most common finding on product reviews; read the trend, then write the sentence, never the reverse.
15. Acceptance criteria for this report
- The data set is complete, reconciled against the source systems, and any exclusion is documented.
- Every CQA and critical IPC is trended with a control chart, a capability index, and a stated run-rule/OOT basis.
- Every signal in section 6 has a disposition and, where escalated, a CAPA reference.
- Stability, MA-variation status, equipment/utility qualification status, and technical agreement currency are all addressed regardless of market.
- Prior period actions are checked for closure and effectiveness.
- The conclusion explicitly answers whether specifications, process, or controls need to change, consistent with the data shown.
- The report is signed, dated, and approved within the SOP’s completion window.
16. References
21 CFR 211.180(e), Annual Product Review requirement (US). 21 CFR 211.192, Production record review / investigations. EU GMP Part I, Chapter 1, section 1.10, Product Quality Review requirement (EU). ICH Q10, Pharmaceutical Quality System. ICH Q9(R1), Quality Risk Management. ICH Q1A(R2) and ICH Q1E, Stability testing and evaluation. FDA Process Validation: General Principles and Practices (2011), Stage 3.
Confirm the current version and clause numbers before issue.
17. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Prepared by (coordinator) | <<FILL>> | ||
| Independent technical reviewer | <<FILL>> | ||
| Approved by (QA) | <<FILL>> |
Filled specimen
The following shows sections 4, 6, and 14 completed for an illustrative solid oral dose product, using the same twelve-batch assay drift worked in the governing article. The company, product, and numbers are illustrative.
Section 4, CQA trending extract, Fictional Tab 10 mg, tablet assay:
| Attribute | Specification | n | Mean | Cpk | Ppk | Run-rule violations | OOT determinations | Trend read |
|---|---|---|---|---|---|---|---|---|
| Assay | 95.0 to 105.0 percent LC | 12 | 98.5 | 1.61 | 1.44 | Nelson rule 3, six or more consecutive points declining, triggered at batch 07 and confirmed through batch 12 | OOT confirmed at batch 11 against the 12-batch historical mean minus 2 SD | Continuous decline across all 12 batches, no reversal; mean sliding toward the lower specification limit |
Section 6, signal register extract:
| Signal | Evidence | Disposition | Basis / CAPA reference |
|---|---|---|---|
| Assay drifting toward lower spec, 12-batch continuous decline | Individuals chart, batches FT-10-001 through FT-10-012 | Escalated | CAPA-2027-0031: confirm reference standard potency and assay column age |
| Dissolution Ppk 1.18, below the internal 1.33 threshold | Capability summary, 12 batches | Justified acceptable | Spread attributable to method variability, mean centered on target, no directional drift across the period; flagged for continued monitoring next period, no CAPA |
Section 14, conclusion extract:
| Question | Answer | Basis |
|---|---|---|
| Do the specifications need to change? | No | Assay remains within specification for all 12 batches; the signal is a process trend, not a specification adequacy question |
| Does the manufacturing process need to change? | Pending CAPA-2027-0031 outcome | Continuous assay decline is unexplained pending investigation; process change will follow the CAPA’s root cause, not precede it |
| Do the in-process controls need to change? | No, at this time | No IPC failure or drift identified independent of the assay signal above |
| Overall product state | Drifting, under active investigation | Section 4 and section 6 |
| CAPAs opened | CAPA-2027-0031 |
Common inspection findings this report prevents
- A report that lists batch counts and complaint counts with no evaluation, failing the “evaluated to determine the need for changes” test.
- Trend charts included with no interpretation, leaving the reader to guess whether anyone actually looked at them.
- A conclusion of “no adverse trends” sitting above a chart that visibly drifts toward a limit.
- Section 6 present but every entry marked “justified acceptable,” with no CAPA ever opened regardless of what the data shows.
- Stability, MA-variation status, or equipment/utility qualification status omitted because the product is US-only and the author wrote to the bare 211.180(e) list instead of the fuller EU list.
- A contract site’s own summary pasted into section 12 without a product-level consolidation.
How to adapt this report
- Set your report number, product, and period in the header, and link it to your APR/PQR SOP.
- Expand section 4 to one row per CQA/critical IPC actually tested for the product; do not compress multiple attributes into one row.
- If reviewing multiple strengths or presentations together (see the product grouping worked example in the governing article), add a sub-table per strength within sections 4 and 5, rolling up to one conclusion in section 14.
- Point section 12 at your real quality agreements by document number, and require the underlying data, not a site summary.
- Confirm every regulation in section 16 against the current published version before issue, including the status of the EU GMP Chapter 1 revision covering product grouping and thin-period PQR content.